NFE2L2 and cancer: Increased survival and drug resistance was associated with high activation of NRF2 and was attributed to the elevated expression of target genes such as antioxidant enzymes, detoxifying enzymes, and drug efflux transporters [9,10,11], whereas NRF2 down-regulation sensitized cancer cells to chemotherapeutic agents [10].